HEPION PHARMACEUTICALS, INC. Debt Conversion, Converted Instrument, Amount
HEPION PHARMACEUTICALS, INC. (HEPA) reported Debt Conversion, Converted Instrument, Amount of $549.98 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-03-31
- HEPION PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2019-06-30 was $400.06K.
- HEPION PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2019-03-31 was $149.92K.
- HEPION PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2019 was $549.98K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|
| 2019-12-31 | $549.98K 10-K · filed 2021-03-31 | ||
| 2019-06-30 | $400.06K 10-Q · filed 2020-11-16 | $549.98K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $149.92K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |